Lilly Presents Updated Results of Retevmo (selpercatinib) in P-I/II (LIBRETTO-001) Trial for Advanced RET Fusion-Positive NSCLC at ELCC 2022

Published: Apr 1, 2022 | Tags: Lilly, Retevmo, selpercatinib, P-I/II, LIBRETTO-001, Trial, Advanced, RET Fusion-Positive, NSCLC, ELCC 2022

Corvia Medical Reports Results of Corvia Atrial Shunt in P-III (REDUCE LAP-HF II) Trial for the Treatment of Heart Failure

Published: Apr 1, 2022 | Tags: Corvia Medical, Corvia Atrial Shunt, P-III, REDUCE LAP-HF II Trial, Heart Failure

InflaRx Reports Results of Vilobelimab in the P-III Part of P-II/III (PANAMO) Study for the Treatment of Severe COVID-19

Published: Apr 1, 2022 | Tags: InflaRx, Vilobelimab, P-III, P-II/III, PANAMO Study, COVID-19

Vertex Reports Results of VX-548 in the Two P-II Proof-of-Concept Studies for the Treatment of Acute Pain

Published: Apr 1, 2022 | Tags: Vertex, VX-548, Two, P-II, Proof-of-Concept Studies, Acute Pain

Horizon Reports the New Analysis of Uplizna (inebilizumab-cdon) in the P-III (N-MOmentum) Trial for Neuromyelitis Optica Spectrum Disorder

Published: Apr 1, 2022 | Tags: Horizon, Uplizna, inebilizumab-cdon, P-III, N-MOmentum Trial, Neuromyelitis Optica Spectrum Disorder

Myeloid Entered into an Exclusive Option & Research Collaboration with Prime Medicine to Develop and Accelerate RetroT Technology for Human Diseases

Published: Apr 1, 2022 | Tags: Myeloid, Prime Medicine, RetroT Technology, Human Diseases

JW Therapeutics Receives the NMPA’s IND Clearance for the Clinical Trial of Carteyva (relmacabtagene autoleucel) as 2L Treatment of Large B-Cell Lymphoma

Published: Mar 31, 2022 | Tags: JW Therapeutics, NMPA, IND, Clearance, Carteyva, Large B-Cell Lymphoma

Numab Entered into a Development and License Agreement with Ono to Develop Immuno-Oncology Therapies for the Treatment of Cancer

Published: Mar 31, 2022 | Tags: Numab, Ono, Immuno-Oncology Therapies, Cancer

Immutep & MSD Published New Interim Data of Eftilagimod Alpha + Keytruda (pembrolizumab) in P-II (TACTI-002) Trial as 2L Treatment of NSCLC at ELCC 2022

Published: Mar 31, 2022 | Tags: Immutep, Eftilagimod Alpha, Keytruda, pembrolizumab, P-II, TACTI-002 Trial NSCLC, ELCC 2022

Taiho Oncology Reports the US FDA’s Acceptance of NDA for Priority Review of Futibatinib for the Treatment of Cholangiocarcinoma

Published: Mar 31, 2022 | Tags: Taiho Oncology, US, FDA, NDA, Priority Review, Futibatinib, Cholangiocarcinoma

Iktos Collaboration with Ono to Develop Innovative Therapies Against Diseases and Pain Using AI Technology

Published: Mar 31, 2022 | Tags: Iktos, Ono, Innovative Therapies, Diseases, AI Technology

Organon Enters into a License Agreement with Daré Bioscience to Commercialize Xaciato (clindamycin phosphate vaginal gel) for the Treatment of Bacterial Vaginosis

Published: Mar 31, 2022 | Tags: Organon, Daré Bioscience, Xaciato, clindamycin phosphate vaginal gel, Bacterial Vaginosis

Antengene’s Eltanexor (ATG-016) Receive the NMPA’s IND Approval for P-II Study to Treat Patients with High-Risk Myelodysplastic Syndromes

Published: Mar 30, 2022 | Tags: Antengene, Eltanexor, ATG-016, NMPA, IND, Approval, P-II Study, Myelodysplastic Syndromes

Ocuphire Reports Results of Nyxol in P-III (MIRA-3) Registration Trial for the Reversal of Pharmacologically-Induced Mydriasis

Published: Mar 30, 2022 | Tags: Ocuphire, Nyxol, P-III, MIRA-3, Registration Trial, Pharmacologically-Induced, Mydriasis

ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) Receives the US FDA’s Approval for Virologically Suppressed Adolescents with HIV

Published: Mar 30, 2022 | Tags: ViiV Healthcare, Cabenuva, cabotegravir, rilpivirine, US, FDA, Approval, Virologically Suppressed, Adolescents, HIV

Pfizer Report Results of Etrasimod in P-III (ELEVATE UC 52) Study for the Treatment of Ulcerative Colitis

Published: Mar 30, 2022 | Tags: Everest, Pfizer, Etrasimod, P-III, ELEVATE UC 52, Study Ulcerative Colitis

Pyxis Oncology In-Licenses BSI-060T From Biosion for the Treatment of Solid Tumors

Published: Mar 30, 2022 | Tags: Pyxis Oncology, In-Licenses, BSI-060T, Biosion, Solid Tumors

Albireo Report Enrollment Completion in P-III (ASSERT) Study of Bylvay (odevixibat) for the Treatment of Alagille Syndrome

Published: Mar 30, 2022 | Tags: Albireo, P-III, ASSERT Study, Bylvay, odevixibat, Alagille Syndrome

UCB’s Fintepla (fenfluramine) Receives the US FDA’s Approval for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

Published: Mar 29, 2022 | Tags: UCB, Fintepla, fenfluramine, US, FDA, Approval, Seizures, Lennox-Gastaut Syndrome

Takeda’s Takhzyro (lanadelumab) Receives the MHLW’s Approval for the Treatment of Prophylaxis Against Acute Attacks of Hereditary Angioedema

Published: Mar 29, 2022 | Tags: Takeda, Takhzyro, lanadelumab, MHLW, Approval, Prophylaxis, Acute Attacks, Hereditary Angioedema

Boehringer Ingelheim Presents Results of Spesolimab in P-II (Effisayil 1) Trial for the Treatment of Generalized Pustular Psoriasis at AAD 2022

Published: Mar 29, 2022 | Tags: Boehringer Ingelheim, Spesolimab, P-II, Effisayil 1 Trial, Generalized Pustular Psoriasis, AAD 2022

Novo Nordisk’s Ozempic Receives the US FDA’s Approval for the Treatment of Type 2 Diabetes

Published: Mar 29, 2022 | Tags: Novo Nordisk, Ozempic, US, FDA, Approval, Type 2 Diabetes

Sanofi Collaborated with IGM Biosciences to Develop & Commercialize IgM Antibody Agonists Against Oncology, Immunology and Inflammation Targets

Published: Mar 29, 2022 | Tags: Sanofi, IGM Biosciences, IgM Antibody Agonists, Oncology, Immunology, Inflammation Targets

BMS Report EMA's Validation for Opdivo (nivolumab) as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

Published: Mar 29, 2022 | Tags: BMS, EMA, Validation, Opdivo, nivolumab, Resectable, Non-Small Cell Lung Cancer

Ipsen’s Cabometyx Receives CHMP's Recommendation for Approval in the EU to Treat Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Published: Mar 28, 2022 | Tags: Ipsen, EMA, CHMP, Cabometyx, Iodine-Refractory, Differentiated Thyroid Cancer

Merck Receives EMA’s CHMP Positive Opinion for Keytruda (pembrolizumab) to Treat MSI-H or dMMR Tumors in Different Types of Cancer

Published: Mar 28, 2022 | Tags: Merck, EMA, CHMP, Keytruda, pembrolizumab,  MSI-H, dMMR Tumors

Dermavant Presents Results of Tapinarof Cream in P-III (PSOARING 3) Trial for the Treatment of Plaque Psoriasis at AAD 2022

Published: Mar 28, 2022 | Tags: Dermavant, Tapinarof Cream, P-III, PSOARING 3 Trial, Plaque Psoriasis, AAD 2022

Arcutis Presents New Pooled Results of Roflumilast in P-III (DERMIS 1 & 2) Trials for the Treatment of Plaque Psoriasis at AAD 2022

Published: Mar 28, 2022 | Tags: Arcutis, Roflumilast, P-III, DERMIS 1 & 2 Trials, Plaque Psoriasis, AAD 2022

Gilead, Eisai and EA Pharma’s Jyseleca (filgotinib) Receive the MHLW’s Approval for the Treatment of Ulcerative Colitis

Published: Mar 28, 2022 | Tags: Gilead, Eisai, EA Pharma, Jyseleca, filgotinib, MHLW, Approval, Ulcerative Colitis

Axsome Entered into a Definitive Agreement to Acquire Sunosi from Jazz for the Treatment of Excessive Daytime Sleepiness

Published: Mar 28, 2022 | Tags: Axsome, Acquire, Sunosi, Jazz, Excessive Daytime Sleepiness

Related Post: PharmaShots Weekly Snapshots (March 21 - 25, 2022)